Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.61 |
| ▸ | WNT3A | P56704 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | RXRG | P48443 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL817710 | 0.97 | CTNNB1 (0.66) | ALDH1A1CTNNB1WNT3APKMTSHR | |
| SCHEMBL7698853 | 0.95 | CTNNB1 (0.64) | ALDH1A1CTNNB1WNT3APKMTSHR | |
| SCHEMBL30089482 | 0.93 | CTNNB1 (0.69) | ALDH1A1CTNNB1WNT3AMAPTTDP1 | |
| SCHEMBL30089540 | 0.89 | CTNNB1 (0.73) | ALDH1A1CTNNB1WNT3ATSHRMAPT | |
| SCHEMBL15988805 | 0.88 | CTNNB1 (0.65) | ALDH1A1CTNNB1WNT3ANR4A2MAPT | |
| SCHEMBL15988780 | 0.85 | CTNNB1 (0.68) | ALDH1A1CTNNB1WNT3ANR4A2MAPT | |
| SCHEMBL19287120 | 0.83 | CTNNB1 (0.55) | ALDH1A1CTNNB1WNT3AMAPTTDP1 | |
| SCHEMBL5662017 | 0.83 | ALDH1A1 (0.58) | ALDH1A1CTNNB1WNT3AMAPTTDP1 | |
| SCHEMBL1114930 | 0.82 | RAB9A (0.56) | ALDH1A1CTNNB1WNT3APKMTSHR | |
| SCHEMBL10405652 | 0.81 | CTNNB1 (0.44) | ALDH1A1CTNNB1WNT3APKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113366-A1 | Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses | UNIVERSITE LOUIS PASTEUR (ETABLISSEMENT PUBLIC A CARACTERE SCIENTIFIQUE, CULTUREL ET PROFESSIONNEL) (FR) | 2005-05-26 | — | — | US | disclosed |
| WO-2002024630-A1 | PHARMACEUTICAL COMPOUNDS USEFUL AS MODULATORS OF ENDOCANNABINOID-MEDIATED RESPONSE | ELI LILLY AND COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-0769015-B1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-03-14 | — | — | EP | disclosed |
| US-5716944-A | USEFUL AS PROPHYLACTIC AND THERAPEUTIC AGENTS OF VARIOUS METABOLIC BONE DISEASES SUCH AS OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0769015-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001267-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-18 | — | — | WO | disclosed |
| US-4435329-A | ANTIHYPERTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| EP-0010347-B1 | NOVEL SUBSTITUTED OMEGA-AROYL(PROPIONYL OR BUTYRYL)-L-PROLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1983-11-09 | — | — | EP | disclosed |
| US-4374249-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1983-02-15 | — | — | US | disclosed |
| US-4226775-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| EP-0010347-A1 | Novel substituted omega-aroyl(propionyl or butyryl)-L-prolines, pharmaceutical compositions containing them and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113366-A1 | Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses | GABRB1, GABRA1, GABRA5 | ALDH1A1 590/4885CTNNB1 1107/4885WNT3A 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.